Loss of heterozygosity on chromosome 10 is considered to be associated with the progression of glioblastomas. Two closely related regions have recently been proposed to contain the glioblastoma suppressor locus on chromosome 10q25-26; a 1 cM region between the polymorphic (CA) n -repeat markers D10S587 and D10S216, and an area of 5 cM between the markers D10S221 and D10S209. To con®rm and further delineate this region, we analyzed 51 glioblastomas and 11 intermediate and low-grade gliomas for loss of heterozygosity on chromosome 10. 47/62 mostly malignant gliomas displayed complete loss of chromosome 10 and nine tumors were unaltered, whereas four glioblastomas and two low-grade oligodendrogliomas had partial loss on distal 10q. With these six tumors, we constructed a deletion map with increased marker density at 10q25-26 which shows two centromeric breakpoints at the markers D10S587 and D10S216, thus only con®rming the distal, but not the proximal candidate glioblastoma suppressor locus. Two out of four low-grade oligodendrogliomas displayed partial deletions on 10q25-26. This suggests that deletion on chromosome 10 is not merely a late event in the progression of glioblastomas, but could play a role earlier in the development of gliomas.
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Glial neoplasms of the central nervous system (CNS) account for the vast majority of primary brain tumors and include astrocytoma, ependymoma, oligodendroglioma, glioblastoma, and tumors of mixed cellular composition (Kleihues et al., 1993) . Glioblastoma multiforme, the most common solid tumor of the adult CNS, represents the undierentiated end stage of glioma tumorigenesis, having a dismal prognosis with a 2 year survival of less than 5% (Walker et al., 1980) .
There is great hope that the discovery of genes involved in tumorigenesis will give rise to novel therapeutic strategies for solid tumors. Studies of allelic loss in human tumors have provided a useful tool for localising and cloning tumor suppressor genes (Cavenee et al., 1985; Friend et al., 1986) . Speci®c genes, such as EGFR on chromosome 7p (Libermann et al., 1985) , p53 on 17p (Nigro et al., 1989) , p16 INK4a / CDKN2 on 9p21 (Kamb et al., 1994; Nobori et al., 1994) , have been shown to be genetically altered in glial neoplasms. Cytogenetic (Bigner et al., 1990; Ransom et al., 1992) and molecular evidence (James et al., 1988; Rasheed et al., 1992; Karlbom et al., 1993; Fults and Pedone, 1993) suggests that deletions on chromosome 10 are among the most frequent genetic alterations in glioblastomas. At least three separate partial deletions have been described ± most consistently loss on chromosome 10q24-26 (Rasheed et al., 1992; Fults and Pedone, 1993 ) ± however, the potential tumor suppressor involved in glioblastoma tumorigenesis has not yet been de®ned. Functional evidence, based on microcell-mediated transfer of major portions of chromosome 10 that caused regression of the neoplastic phenotype, lends further support to the presence of a glioblastoma suppressor gene on 10q24-26 (Steck et al., 1995) . It is not known whether this putative suppressor is further implicated in the development of other glial neoplasms of oligodendrocytic or ependymal origin.
Recently, two closely related, but distinct regions on chromosome 10q25-26 have been implicated to harbor the glioblastoma suppressor gene (Albarosa et al., 1996; Rasheed et al., 1995) . By high density mapping, we de®ned two centromeric breakpoints in a glioblastoma and in a low-grade oligodendroglioma. Both point to the same 1 cM region which has been proposed to harbor the glioblastoma suppressor gene (Rasheed et al., 1995) .
Gliomas of dierent histopathological subtypes were directly obtained from surgery and classi®ed by two experienced neuropathologists according to the World Health Organisation (WHO) as summarised in Table 1 . Using polymerase chain reaction (PCR) and the conditions previously described (Merlo et al., 1994) , DNA from glial tumor specimens and lymphocytes was analysed for loss of LOH by ampli®cation of dinucleotide and tetranucleotide repeat-containing sequences. We used 25 polymorphic (CA) n -dinucleotide repeat markers and two polymorphic (GATA) n tetranucleotide repeat markers (D10S675 and D10S676), as shown in Figure 1 . Primers for these microsatellite markers were obtained from Research Genetics (Huntsville, AL). For microsatellite analysis, the forward primer was labeled with T4-polynucleotide kinase (New England Biolabs) and [g-32 P]ATP. PCRampli®ed products were separated using 7% polyacrylamide-formamide gel electrophoresis in denaturing 5.6 M urea followed by autoradiography at 7808C overnight. For informative cases, allelic loss was scored if the radiographic signal of one allele was at least 50% less in tumor DNA as compared to the corresponding normal allele.
Initially, we analysed 51 glioblastomas, two anaplastic astrocytomas, three low-grade astrocytomas, two anaplastic mixed oligoastrocytomas and four low-grade oligodendrogliomas for loss of heterozygosity on chromosome 10, using 17 polymorphic microsatellite markers. Complete loss of these 17 markers was found in 45/51 glioblastomas (88%) and in 2/2 anaplastic mixed oligoastrocytomas (100%) which were therefore excluded from further analysis. From the remaining 15 gliomas, nine tumors (2/51 glioblastomas, 2/2 anaplas- Figure 1 Deletion map displays partial LOH on chromosome 10q25-26 in six gliomas (four glioblastomas, GBM11, GBM991, GBM6, GBM946; two oligodendrogliomas WHO grade II, OG50, OG40). The map position of the 27 microsatellite marker used is listed according to the integrated map of chromosome 10 on the left (Moschonas, 1996) . The bracketed areas denote two published candidate regions on 10q25 (Albarosa et al., 1996; Rasheed et al., 1995); our own minimal area of loss is shown below between markers D10214 and D10S212. Black rectangles, LOH; white rectangles, retention of both informative alleles; SH, shift (allelic expansion or deletion); NI, not informative Table 1 . With regard to overall genetic alterations, 49/51 glioblastomas (96%), 2/2 mixed anaplastic oligoastrocytomas (100%) and 2/4 low-grade oligodendrogliomas (50%) displayed either partial or complete loss on chromosome 10.
Our initial mapping data, based on four glioblastomas and two low-grade oligodendrogliomas with partial LOH pointed to a large region of approximately 23 cM on 10q25-26 potentially harboring a glioma suppressor locus. To increase mapping resolution, we used 10 additional polymorphic dinucleotide (CA) n -repeat markers from this area (Gyapay et al., 1994) . The results obtained from these six tumors are summarized in Figure 1 . Mapping data and autoradiographs, as shown in Figure 2 , demonstrate the centromeric breakpoints in the two most informative gliomas, a glioblastoma (GBM 946) and a low-grade oligodendroglioma (OG40). These two tumors con®rm one of the two closely related regions with a 1 cM area bounded by the markers D10S587 and D10S216 which has previously been suspected to harbor a glioblastoma suppressor gene (Rasheed et al., 1995) . However, it would exclude the other candidate region between the markers D10S221 and D10S209 (Albarosa et al., 1996) that lies more towards the centromere. Taking together our mapping data and the data published (Rasheed et al., 1995) , the putative suppressor gene would lie adjacent to the dinucleotide marker D10S216. Moreover, the recombination event in glioblastoma GBM946, as shown in Figure 2 , might lend further support to this notion. In this tumor, the very distal markers on 10q25-26 display nearly complete allelic loss while the marker D10S216 at the breakpoint only shows a partial loss of the larger allele whereas more proximal markers clearly retain both copies of chromosome 10. This partial loss of one allele of the marker D10S216 could be accounted for by the presence of a subpopulation of cells within the tumor that has acquired an additional loss at the marker D10S216 later on during progression. This would imply that two distinct recombination events ± an initial deletion telomeric to D10S216 followed by a second deletion at D10S216 ± might have occurred in this tumor. Interestingly, two deletions within the same allele have recently been described in the novel TSG101 tumor susceptibility gene in human breast cancers (Li et al., 1997) .
The order of microsatellite markers listed in Figure 1 is based on the published order of a YAC contig in the chromosome 10q25-q26.1 region (Moschonas, 1996) . In addition, the marker D10S575 has been mapped to a region approximately 5 cM telomeric to the marker D10S216 (Gyapay et al., 1994) , and the marker D10S214, which was not informative in GBM946 and OG40, has been genetically mapped to the same locus as marker D10S575 (Gyapay et al., 1994) . Unequivocal evidence about marker order in this area depends upon a de®nitive physical map.
LOH on chromosome 10 is considered to be a late step in the progression of glioblastomas (James et al.,
1988). The fact that we found partial LOH in 2/4 (50%) low-grade oligodendrogliomas in this critical region suggests that the putative glioblastoma suppressor locus could be involved earlier in glioma tumorigenesis. Deletions on chromosome 10q25-26 have rarely been reported in oligodendrogliomas (Wu et al., 1993; Venter and Thomas, 1991) , a distinct entity of gliomas that arise from oligodendrocytes which produce the CNS myelin. Even though histopathologi- 
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Figure 2 LOH analysis on chromosome 10 for two selected gliomas. Polymorphic chromosome 10 microsatellite markers were ampli®ed from DNA derived from normal peripheral blood lymphocytes (N) and from microdissected tumor tissue (T). In glioblastoma GBM946 and in oligodendroglioma OG40 (WHO grade II), centromeric breakpoints are shown between the markers D10S587 and D10S216 and between D10S216 and D10S575 on chromosome 10q25, respectively. Arrowheads denote loss of one allele consistent with LOH cal criteria to classify a given tumor might be applied dierently even by experienced neuropathologists, it is nevertheless a remarkable ®nding that another lowgrade glioma (OG50) con®rmed the most informative deletion found in oligodendroglioma OG40. In the former case, a relatively benign course with prolonged survival for more than 7 years from the initial diagnosis excludes an intermediate or high grade glioma. Of course, the real frequency of genetic changes in oligodendrogliomas on chromosome 10q25-26 will have to be assessed by an extended LOH study of this relatively rare tumor type. Nine gliomas, predominantly of lower malignancy grades, showed retention of both alleles at all loci tested, indicating that no gross genetic rearrangement on chromosome 10 is associated with tumor development in a subfraction of gliomas. This does, however, not rule out minor bi-allelic genetic alterations such as microdeletions or point mutations of the putative glioma suppressor gene.
All seven markers assigned to chromosome 10p did not show any partial deletions, therefore not supporting an additional suppressor locus on 10p. However, most of our tumors (88%) had lost one entire copy of chromosome 10, and are therefore not informative to comment on the putative 10p region (Karlbom et al., 1993; Ransom et al., 1992; Steck et al., 1995) .
In conclusion, we found two centromeric breakpoints that con®rm one of the two suspected glioblastoma suppressor loci at the marker D10S216 on chromosome 10q25-26. Moreover, this locus appears to also be involved in low-grade oligodendrogliomas ± a new candidate region for oligodendrocyte-derived neoplasms ± suggesting that deletions on chromosome 10 are not merely a late event in the progression of glioblastomas, but could play a role earlier in glioma tumorigenesis.
